Search
Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.
AACR Project GENIE steering committee head and Chair of MSK’s Human Oncology and Pathogenesis Program, Dr. Charles Sawyers, discusses how the first batch of genomic sequencing data fulfills an unmet need in oncology.
Scientists have learned that a drug activates a form of highly inflammatory programmed cell death called pyroptosis — a discovery that sheds light on immune function.
The risk of breast cancer increases as you age. MSK has breast cancer experts with special training and experience treating older patients.
Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that it is ranked among one of the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers published by the Institute for Scientific Information at Clarivate.
Learn about seven nursing staff members were honored with a Robbins Family Award for Nursing Excellence.
Memorial Sloan Kettering Cancer Center has announced the appointment of medical oncologist Paul Sabbatini to the new position of Deputy Physician-in-Chief for Clinical Research.
Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.
Animal model research from MSK has shown for the first time that fasting can reprogram the metabolism of natural killer cells, helping them to survive in the harsh environment in and around tumors, while also improving their cancer-fighting ability.
Doctors are developing treatment strategies that target the androgen receptor, which is found in many triple-negative breast cancers.